The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Antibody persistence and the effect of a booster dose given 5, 10 or 15years after vaccinating preadolescents with a recombinant hepatitis B vaccine
Gilca V, De Serres G, Boulianne N, Murphy D, De Wals P, Ouakki M, Trudeau G, Massé R, Dionne M. Vaccine. 2012 Dec 1. pii: S0264-410X(12)01630-1. doi: 10.1016/j.vaccine.2012.11.037. [Epub ahead of print]
Source
Institut National de Santé Publique du Québec, Université Laval, Québec, Canada. Electronic address: vladimir.gilca@ssss.gouv.qc.ca.
Abstract
The persistence of antibody obtained post-vaccination of preadolescents with three doses of Engerix-B and the effect of a booster administered 5, 10 or 15years later were monitored in 663 vaccinees. Five, 10 and 15years post-vaccination >94% of subjects had detectable antibodies and 88.2%, 86.4% and 76.7% had a titre ≥10IU/L; GMTs were 269IU/L, 169IU/L and 51IU/L, respectively; 99.1-100% vaccinees reached a titre ≥10IU/l post-booster. GMTs were 118012IU/L, 32477IU/L, and 13946IU/L when the booster was administered 5, 10 or 15 years post-vaccination, respectively. We conclude that vaccination induces immunity in the great majority of vaccinees for at least 15years. The response to a booster dose suggests persistence of immune memory in almost all vaccinees. Although a booster dose increases substantially anti-HBs titres, the clinical relevance of such an increase remains unknown. These results do not support the need of a booster for at least 15years when vaccinating preadolescents with Engerix-B.